Celularity ( (CELU) ) has released a notification of late filing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celularity Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company’s annual report on Form 10-K (Yearly Report) is the subject filing, and the notification confirms that this yearly report could not be filed on time with the U.S. Securities and Exchange Commission.
The company cites constraints in its liquidity position and limited financial accounting staffing as the main reasons for the delay. These pressures have slowed the financial close and reporting process, including the preparation of consolidated financial statements, and made it impractical to complete the Form 10-K (Yearly Report) within the normal deadline.
Celularity states that it expects to file the delayed Form 10-K (Yearly Report) on or before the 15th calendar day following the prescribed due date. The company also notes that it is working diligently to complete the necessary work and intends to submit the annual filing as soon as practicable within this extension window.
Importantly for investors, Celularity indicates that it does not anticipate any significant change in results of operations compared with the prior fiscal year to be reflected in the earnings statements in the upcoming Form 10-K (Yearly Report). This statement is still forward-looking in nature, meaning actual results could differ once the full audited financials are published.
The company affirms that all other required periodic filings over the past 12 months have been submitted, underscoring continued baseline compliance with SEC reporting rules. The notification is signed on behalf of Celularity by Acting Chief Financial Officer John Sprague, dated March 31, 2026, signaling executive oversight of the delay and the ongoing efforts to complete the annual report.
The most recent analyst rating on (CELU) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Neutral.
The score is primarily weighed down by weak financial performance—large ongoing losses, declining revenue, and negative equity with meaningful debt. Technicals also point to a sustained downtrend with weak momentum. Valuation offers limited support given negative earnings and no dividend, while recent corporate events are mixed: liquidity improved via financing, but dilution/regulatory and shareholder constraints remain.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Celularity Inc. is a biotechnology company based in Florham Park, New Jersey. It develops cellular therapies and related technologies, focusing on products derived from human cells for potential medical applications.
Average Trading Volume: 159,719
Technical Sentiment Signal: Sell
Current Market Cap: $36.34M
Learn more about CELU stock on TipRanks’ Stock Analysis page.